Clinical trial
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate…
NCT00075192 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00075192 |
|---|---|
| Title | CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer |
| Official title | A Phase 1, Open Label, Non-Randomized, Dose Escalation Study to Evaluate the Safety of CP-675,206 in Combination With Neoadjuvant Androgen Ablation and a Phase 2, Open Label, Randomized Study to Evaluate the Efficacy of CP-675,206 in Combination With Neoadjuvant Androgen Ablation and Androgen… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | CP-675, 206 and leuprolide acetate and bicalutamide, leuprolide acetate and bicalutamide |
| Enrollment | 8 |
| Start date | Mar 1, 2004 |
| Completion | Mar 1, 2006 |
| First posted | Jan 7, 2004 |
| Last update posted | Jun 6, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: